Development and characterization of nanobody against envenomation by Naja naja oxiana

Akbar Oghalaie,Mohammad Hosseininejad-Chafi,Hiba Mejri,Mohammad Reza Zareinejad,Balkiss Bouhaouala-Zahar,Kamran Pooshang Bagheri,Hasan Mirzahoseini,Delavar Shahbazzadeh,Mahdi Behdani,Fatemeh Kazemi-Lomedasht
DOI: https://doi.org/10.1016/j.toxicon.2024.108057
IF: 3.035
2024-08-03
Toxicon
Abstract:Snakebites are considered a significant health issue. Current antivenoms contain polyclonal antibodies, which vary in their specificity against different venom components. Development and characterization of next generation antivenoms including nanobodies against Naja naja oxiana was the main aim of this study. Crude venom was injected into the Sephadex G50 filtration gel chromatography column and then toxic fractions were obtained. Then the corresponding fraction was injected into the HPLC column and the toxic peaks were identified. N. naja oxiana venom was injected into a camel and specific nanobodies screening was performed against the toxic peak using phage display technique. The obtained results showed that among the 12 clones obtained, N24 nanobody was capable of neutralizing P1, the most toxic peak obtained from HPLC chromatography. The molecular weight of P1 was measured with a mass spectrometer and was found to be about seven kDa. The results of the neutralization test of crude N. naja oxiana venom with N24 nanobody showed that 250 μg of recombinant nanobody could neutralize the toxic effects of 20 μg equivalent to LD50 × 10 of crude venom in mice. The findings indicate the potential of the developed nanobody to serve as a novel antivenom therapy.
What problem does this paper attempt to address?